
    this study was terminated due to the efficacy results from an interim analysis (at the end of
    treatment epoch) of the phase ii study cqge031b2201 (nct01716754).
  
['asthma']
['qge031', 'placebo']

        Key Inclusion Criteria:

          -  A diagnosis of allergic asthma, uncontrolled on current medication.

          -  History of at least 2 asthma exacerbations during the last 1 year

          -  Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted
             normal value; reversibility following administration of bronchodilator.

        Key Exclusion Criteria:

          -  Use of tobacco products within the previous 6 months (Social occasional smokers may be
             included).

          -  Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.
      